glucose-responsive insulin
/ Ipsen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 14, 2017
New diabetes drugs in development
- "John B. Buse, MD, PhD...recently spoke on new drugs in development at the 64th annual American Diabetes Association's Advanced Postgraduate Course....'The question is whether we eventually will be using those agents exclusively instead of basal insulin, or what their place will be in the therapeutic landscape.'...Ertugliflozin is a new SGLT-2 inhibitor that is under review by the US Food and Drug Administration....Sotagliflozin, an SGLT-1/SGLT-2 dual inhibitor, is another agent that is well advanced into phase 3 trials in patients with type 1 diabetes."
Media quote
1 to 1
Of
1
Go to page
1